| Literature DB >> 10974186 |
Abstract
Platelet membrane glycoprotein IIb/IIIa inhibitors, a new class of potent antiplatelet agents, have been used in the treatment of acute coronary syndromes as well as in the prevention of complications after percutaneous coronary interventions. Approximately 50,000 patients with coronary artery disease have been enrolled in randomized studies of glycoprotein IIb/IIIa inhibitors. The purpose of this article is to review the pharmacology of glycoprotein IIb/IIIa inhibitors, the results of the clinical trials using these agents, and their current use in percutaneous coronary interventions and the treatment of acute coronary syndromes.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10974186 DOI： 10.1016/s0002-9343(00)00474-5
Source DB: PubMed Journal: Am J Med ISSN： 0002-9343 Impact factor: 4.965